Clinical trials: Diabetic Macular Edema
Diabetic Macular Edema
Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections.
- Trial name
- NCT00040313
- Testing
- pegaptanib sodium (Macugen)
- Sponsor
- Eyetech Pharmaceuticals
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema
Ocular Safety and Usability Study for FYB203 PFS
The objective of the study is to assess the ocular safety of the FYB203 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema
- Trial name
- NCT06708637
- Testing
- FYB203 2 mg (0.05 mL of 40 mg/mL)
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Formycon AG
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Macular Edema
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
- Trial name
- NCT02188173
- Testing
- dexamethasone 700 ㎍ intravitreal implant
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Allergan
Visual Impairment Due to Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema.
- Trial name
- RELATION (NCT01131585)
- Testing
- Active laser photocoagulation, Ranibizumab 0.5 mg
- Where
- 34 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
The purpose of this study is to generate additional safety and effectiveness data in Indian Diabetic macular edema (DME) patients that more closely resemble the real-world population intended to be treated with Brolucizumab.
- Trial name
- NCT05959304
- Testing
- brolucizumab
- Where
- 8 sites in India
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLIMMER (NCT04603937)
- Testing
- KSI-301, Aflibercept
- Where
- 72 sites in United States, Czechia and 6 more
- Volunteers
- 459 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Macular Edema
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME).
- Trial name
- NEW DAY (NCT04469595)
- Testing
- Iluvien 0.19 MG Drug Implant, Aflibercept
- Where
- 40 sites in United States
- Volunteers
- 300 people
- Sponsor
- Alimera Sciences
Diabetic Macular Oedema, Retinal Vein Occlusion with Macular Oedema
Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy
This trial is a phase II, multi-center, single-masked (assessors) dose-ranging study designed to evaluate the comparative safety and preliminary efficacy of two dosage regimens of the IBE-814 IVT Dexamethasone Implant in patients…
- Trial name
- NCT04576689
- Testing
- IBE-814 70ug, IBE-814 140ug
- Where
- 21 sites in Australia, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Ripple Therapeutics Pty Ltd
Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD)
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
This is an observational study in which only data are collected from people who have already been prescribed aflibercept 8 mg by their own doctors.
- Conditions
- Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME)
- Trial name
- NCT06075147
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- 18 sites in Australia, Canada and 16 more
- Volunteers
- 2,500 people
- Sponsor
- Bayer
Diabetic Macular Edema
A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema
Researchers are looking for a better way to treat people who have diabetic macular edema. Diabetic macular edema (DME) is a diabetes-related eye disorder.
- Trial name
- PHOTONiC (NCT06422507)
- Testing
- 8 mg aflibercept (BAY 86-5321) (High Dose), 2 mg aflibercept (EYLEA, BAY 86-5321)
- Where
- 52 sites in China, Hong Kong
- Volunteers
- 333 people
- Sponsor
- Bayer
Retinal Vein Occlusion, Age Related Macular Degeneration
Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion…
- Trial name
- NCT02140411
- Testing
- Ranibizumab Intravitreal injections
- Where
- Chile
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Macular Degeneration
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
This pilot study will evaluate home vision testing using a mobile medical application in participants with diabetic macular edema (DME) or neovascular age-related macula degeneration (nAMD) who receive intravitreal ranibizumab…
- Trial name
- NCT02420132
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT)…
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
- Trial name
- GenSci148-101 (NCT07817615)
- Testing
- GenSci148 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Diabetic Macular Edema, Diabetic Retinopathy
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma…
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Macular Degeneration
- Trial name
- NCT06305416
- Testing
- Ranibizumab 10mg/ml Injection, Lucentis
- Where
- Bangladesh
- Volunteers
- 70 people
- Sponsor
- Incepta Pharmaceuticals Ltd
Macular Edema
Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.
To evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU Label.
- Trial name
- AQUA (NCT02581995)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- 76 sites in Austria, Canada and 12 more
- Volunteers
- 560 people
- Sponsor
- Bayer
Age-Related Macular Degeneration, Retinal Vein Occlusion
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval…
- Conditions
- Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01573572
- Testing
- pegaptanib sodium injection
- Where
- 4 sites in United States
- Volunteers
- 131 people
- Sponsor
- Bausch & Lomb Incorporated
Diabetic Macular Edema
First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers
This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.
- Trial name
- NCT04795037
- Testing
- CU06-1004, Single dose, CU06-1004, Multiple doses
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Curacle Co., Ltd.
Retinopathy, Diabetic
A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema
The purpose of this study is to characterize the systemic and ocular safety and tolerability, pharmacokinetics, exploratory efficacy and pharmacodynamics of 3 months of repeat administration of oral darapladib in diabetic macular…
- Trial name
- NCT01506895
- Testing
- darapladib
- Where
- 16 sites in Australia, Denmark and 3 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Eye Diseases
Study for Collection of Aflibercept Data in Routine Practice
The French CODEX study is designed as a national database to describe, in routine medical practice, functional and anatomical responses to intravitreal Aflibercept injection, in a large population of anti-VGEF-naïve patients…
- Trial name
- CODEX (NCT02811692)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- France
- Volunteers
- 425 people
- Sponsor
- Bayer